53 related articles for article (PubMed ID: 21497162)
21. Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma.
Mayevska O; Shuvayeva H; Igumentseva N; Havrylov S; Basaraba O; Bobak Y; Barska M; Volod'ko N; Baranska J; Buchman V; Drobot L
Exp Oncol; 2006 Dec; 28(4):275-81. PubMed ID: 17285110
[TBL] [Abstract][Full Text] [Related]
22. Extended substrate specificity of opossum chymase--implications for the origin of mast cell chymases.
Reimer JM; Enoksson M; Samollow PB; Hellman L
Mol Immunol; 2008 Apr; 45(7):2116-25. PubMed ID: 18022236
[TBL] [Abstract][Full Text] [Related]
23. A three-dimensional molecular model of lipid-free apolipoprotein A-I determined by cross-linking/mass spectrometry and sequence threading.
Silva RA; Hilliard GM; Fang J; Macha S; Davidson WS
Biochemistry; 2005 Mar; 44(8):2759-69. PubMed ID: 15723520
[TBL] [Abstract][Full Text] [Related]
24. Establishment and evaluation of 2 monoclonal antibodies against oxidized apolipoprotein A-I (apoA-I) and its application to determine blood oxidized apoA-I levels.
Ueda M; Hayase Y; Mashiba S
Clin Chim Acta; 2007 Mar; 378(1-2):105-11. PubMed ID: 17174291
[TBL] [Abstract][Full Text] [Related]
25. Cleaved SLPI, a novel biomarker of chymase activity.
Belkowski SM; Masucci J; Mahan A; Kervinen J; Olson M; de Garavilla L; D'Andrea MR
Biol Chem; 2008 Sep; 389(9):1219-24. PubMed ID: 18713008
[TBL] [Abstract][Full Text] [Related]
26. Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.
DiDonato JA; Aulak K; Huang Y; Wagner M; Gerstenecker G; Topbas C; Gogonea V; DiDonato AJ; Tang WHW; Mehl RA; Fox PL; Plow EF; Smith JD; Fisher EA; Hazen SL
J Biol Chem; 2014 Apr; 289(15):10276-10292. PubMed ID: 24558038
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies specific for different regions of human apolipoprotein A-I. Characterization of an antibody that does not bind to a genetic variant of apoA-I (Glu----136 Lys).
Ehnholm C; Lukka M; Rostedt I; Harper K
J Lipid Res; 1986 Dec; 27(12):1259-64. PubMed ID: 2435827
[TBL] [Abstract][Full Text] [Related]
28. The neutral protease chymase degrades apolipoprotein E from high-density lipoproteins.
Lee-Rueckert M; von Eckardstein A; Kovanen PT
Clin Chem Lab Med; 2008; 46(3):421-3. PubMed ID: 18254717
[No Abstract] [Full Text] [Related]
29. A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis.
Jacobs-Cachá C; Puig-Gay N; Helm D; Rettel M; Sellarès J; Meseguer A; Savitski MM; Moreso FJ; Soler MJ; Seron D; Lopez-Hellin J
Sci Rep; 2020 Jan; 10(1):1159. PubMed ID: 31980684
[TBL] [Abstract][Full Text] [Related]
30. A cDNA-dependent scintillation proximity assay for quantifying apolipoprotein A-I.
Hanselman JC; Schwab DA; Rea TJ; Bisgaier CL; Pape ME
J Lipid Res; 1997 Nov; 38(11):2365-73. PubMed ID: 9392434
[TBL] [Abstract][Full Text] [Related]
31. Development of a newly immunoassay specific for mouse presepsin (sCD14-ST).
Takahashi G; Hoshikawa K; Suzuki R; Sato K; Hoshi S; Yoshinao D; Shirakawa K
Sci Rep; 2022 Dec; 12(1):21724. PubMed ID: 36522357
[TBL] [Abstract][Full Text] [Related]
32. Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis.
Takai S; Jin D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066113
[TBL] [Abstract][Full Text] [Related]
33. Disruption in the balance between apolipoprotein A-I and mast cell chymase in chronic hypersensitivity pneumonitis.
Inoue Y; Okamoto T; Honda T; Nukui Y; Akashi T; Takemura T; Tozuka M; Miyazaki Y
Immun Inflamm Dis; 2020 Dec; 8(4):659-671. PubMed ID: 33016012
[TBL] [Abstract][Full Text] [Related]
34. Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr
Kareinen I; Baumann M; Nguyen SD; Maaninka K; Anisimov A; Tozuka M; Jauhiainen M; Lee-Rueckert M; Kovanen PT
J Lipid Res; 2018 Jun; 59(6):945-957. PubMed ID: 29581158
[TBL] [Abstract][Full Text] [Related]
35. High-Density Lipoprotein Binds to Mycobacterium avium and Affects the Infection of THP-1 Macrophages.
Ichimura N; Sato M; Yoshimoto A; Yano K; Ohkawa R; Kasama T; Tozuka M
J Lipids; 2016; 2016():4353620. PubMed ID: 27516907
[TBL] [Abstract][Full Text] [Related]
36. Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.
Nguyen SD; Maaninka K; Lappalainen J; Nurmi K; Metso J; Öörni K; Navab M; Fogelman AM; Jauhiainen M; Lee-Rueckert M; Kovanen PT
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):274-84. PubMed ID: 26681753
[TBL] [Abstract][Full Text] [Related]
37. A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients.
Cubedo J; Padró T; García-Arguinzonis M; Vilahur G; Miñambres I; Pou JM; Ybarra J; Badimon L
J Lipid Res; 2015 Sep; 56(9):1762-73. PubMed ID: 26168996
[TBL] [Abstract][Full Text] [Related]
38. Mast cells as effectors in atherosclerosis.
Bot I; Shi GP; Kovanen PT
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):265-71. PubMed ID: 25104798
[TBL] [Abstract][Full Text] [Related]
39. Identification of sites in apolipoprotein A-I susceptible to chymase and carboxypeptidase A digestion.
Usami Y; Kobayashi Y; Kameda T; Miyazaki A; Matsuda K; Sugano M; Kawasaki K; Kurihara Y; Kasama T; Tozuka M
Biosci Rep; 2012 Dec; 33(1):49-56. PubMed ID: 23072735
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
